Scribe Therapeutics Inc.
SCTXHealthcare|Biotechnology|US
$15.70
+0.22 (+1.42%)
About
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
Stock Price
-27.5%(1Y)
1M
-18.4%
3M
-39.6%
6M
-27.5%
YTD
-27.5%
1Y
-27.5%
3Y
-27.5%
5Y
-27.5%
Pipeline Summary
1 total trials1
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 1
Active Trials (1)
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
NCT07428473Elevated LDL-C and High Cholesterol
Phase 1Recruiting
Enrollment: 64 participants
Key Facts
Market Cap$254.1M
Employees82
CEOBenjamin L. Oakes
IPO DateJul 24, 2026
Beta0.00
52-Week Range$13.5 – $39.6
Avg Volume370,897
ExchangeNASDAQ
Websitescribetx.com
Ownership
Float10.5%
Shares Outstanding16.2M
Recent Insider Trades
AH Bio Fund II, L.P.BUY
Jul 27, 2026333,333 shares @ $15.00
AH Bio Fund II, L.P.CONVERSION
Jul 27, 20262,051,742 shares
AH Bio Fund II, L.P.CONVERSION
Jul 27, 2026697,650 shares
AH Bio Fund II, L.P.CONVERSION
Jul 27, 20264,131,344 shares
AH Bio Fund II, L.P.CONVERSION
Jul 27, 202612,150,003 shares
Recent News
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Nov 5, 2026 · globenewswire.com
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026
Nov 4, 2026 · globenewswire.com
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Oct 20, 2026 · fool.com
Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst
Oct 15, 2026 · seekingalpha.com
Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Rated “Moderate Buy” by Wall Street Analysts
Sep 28, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:33 AM